Topic: acute myeloid leukemia (AML)
The FDA placed a partial clinical hold on a bispecific antibody in development for acute myeloid leukemia following reports of two patient deaths.
The funding will advance Vor's lead asset, an engineered hematopoietic stem cell therapy for acute myeloid leukemia.
BMS and Eisai spinoff H3 Biomedicine will conduct research aimed at developing immune therapies for cancer using the latter’s RNA-splicing platform.
The week’s news included antibodies that lower the risks of bone marrow transplants and a new way to target a mutation in epilepsy.
Two dual EGFR/HER2 inhibitors from Boehringer Ingelheim and Puma showed in vitro activity against AML cancer cells.
Tolero Pharmaceuticals has inked a pact to test its CDK9 inhibitor, alvocidib, in combination with AbbVie’s Venclexta in relapsed/refractory AML.
NewLink has cut its headcount by a third to buy the time it needs to prove that—despite setbacks—its IDO inhibitor indoximod is still worth pursuing.